1. "Elsevier Inc."
Formats
  1. Journal Article (7386)
  2. Meeting Abstract (4694)
  3. Review (617)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Publishers
  1. Elsevier Inc. (13855)

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer
    Meeting Abstract

    Sabbatini, P.; Brown, J.; Peters, W. A.; Jacobs, A.; Mehdi, A.; Crozier, M. A.; Rivkin, S.; Bolton, M. G.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens
    Meeting Abstract

    Papadimitrakopoulou, V.; Figlin, R.; Garland, L.; von Hoff, D.; Kris, M.; Purdom, M.; Brown, G. L.; Maack, C.; Macpherson, J.; Henner, W. D.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A novel class of pyridopyrimidine tyrosine kinase inhibitors blocks cancer cells in the S-phase of the cell cycle
    Meeting Abstract

    Mizenina, O.; Moasser, M.; Rosen, N.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Role of Id proteins in tumor angiogenesis
    Meeting Abstract

    Mittal, V.; Schoer, R.; Ruzinova, M.; Benezra, R.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Measuring response to therapy with molecular imaging
    Meeting Abstract

    Larson, S. M.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Inhibition of activated DNA transcription by Ecteinascidin 743 (ET-743)
    Meeting Abstract

    Kolb, E. A.; Hu, Z.; Friedman, D.; Scotto, K.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase 2 study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer
    Meeting Abstract

    Kavanagh, J. J.; Kudelka, A.; Spriggs, D. R.; Bookman, M. A.; Lewis, L.; Maack, C.; Dombroski, J.; Macpherson, J.; Henner, W. D.; Brown, G. L.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A phase I study of the novel high affinity VEGF blocker VEGF trap in patients with refractory solid tumors and lymphoma
    Meeting Abstract

    Dupont, J.; Pezzulli, S.; Gordon, M.; Mendelson, D.; Murren, J.; Hsu, A.; Holash, J.; Stahl, N.; Cedarbaum, J.; Spriggs, D. R.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • 17AAG low target binding affinity and potent whole cell potency: Finding an explanation
    Meeting Abstract

    Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Neckers, L.; Whitesell, L.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save